How do I interpret my genomic profiling results for Ovarian Cancer

Understanding Your Ovarian Cancer Genomic Profiling Results

Genomic profiling is a powerful tool that analyzes your tumor's DNA to identify specific mutations and characteristics that guide treatment decisions. Let me walk you through what these results mean and how to use them.

What Genomic Profiling Does

Genomic profiling examines the genetic "instructions" in your cancer cells to find mutations—changes in DNA that drive tumor growth. Think of it like getting a detailed map of your tumor's vulnerabilities, which helps your oncologist select treatments most likely to work for YOUR specific cancer.

According to the NCCN Guidelines for Ovarian Cancer, tumor molecular analysis should be performed both at initial diagnosis and if your cancer recurs, because different mutations may appear over time.

---

Key Biomarkers Your Results Should Include

1. BRCA1/2 Mutations (Most Important)

What it means: These genes normally repair damaged DNA. If you have a BRCA mutation, your cells can't repair DNA damage effectively.

Why it matters:

• BRCA mutations are found in approximately 15-20% of ovarian cancer patients
• This status dramatically changes your treatment options
• If positive, you're eligible for PARP inhibitors (drugs like olaparib, niraparib, rucaparib) that exploit this weakness

Questions to ask your doctor:

• Do I have a BRCA1 or BRCA2 mutation?
• If positive, am I eligible for PARP inhibitor maintenance therapy?
• Should my family members be tested?

---

2. Homologous Recombination Deficiency (HRD) Status

What it means: This measures whether your tumor cells can repair DNA damage through a specific pathway called homologous recombination. HRD-positive tumors have defective DNA repair.

Why it matters:

• HRD-positive cancers respond better to platinum-based chemotherapy AND PARP inhibitors
• Even without a BRCA mutation, HRD status predicts treatment response
• According to NCCN Guidelines, HRD testing is recommended for patients without BRCA mutations

What the results mean:

• HRD-positive (or HRD-high): Your tumor has significant DNA repair defects → PARP inhibitors are likely beneficial
• HRD-negative (or HRD-low): Your tumor has better DNA repair ability → Different treatment approaches may be considered

Questions to ask your doctor:

• What is my HRD status?
• How does this affect my maintenance therapy options?
• Are there clinical trials for HRD-positive ovarian cancer?

---

3. Other Important Biomarkers

According to NCCN Guidelines, your results may also include:

| Biomarker | What It Means | Why It Matters | |-----------|--------------|----------------| | MSI/MMR (Microsatellite Instability / Mismatch Repair) | Defects in DNA proofreading systems | May indicate eligibility for immunotherapy trials | | TMB (Tumor Mutational Burden) | Total number of mutations in your tumor | Higher TMB may predict immunotherapy response | | HER2 Status | Protein levels on cancer cells | Identifies patients for targeted therapies | | FOLR1 (FRα) | Folate receptor expression | Emerging target for new therapies | | BRAF, NTRK, RET | Specific gene mutations | Identify patients for targeted drug trials |

---

How to Read Your Report

Your genomic profiling report should include:

✅ Test name (e.g., "Comprehensive Tumor Genomic Analysis")
✅ Specific mutations found (or "no mutations detected")
✅ Interpretation (what each finding means)
✅ Clinical significance (how it affects treatment)
✅ Recommendations (suggested treatment approaches)

Red flags if your report is unclear:

• Lacks specific mutation names
• Doesn't explain clinical significance
• Doesn't mention BRCA or HRD status
• Seems incomplete or vague

---

What to Do With Your Results

Step 1: Understand Your Status

Ask your oncologist to explain:

• Which mutations were found (or not found)
• What each means for your specific situation
• How this changes your treatment plan

Step 2: Discuss Treatment Implications

According to NCCN Guidelines, your molecular results should inform:

• First-line treatment: Initial chemotherapy + targeted therapy combinations
• Maintenance therapy: Long-term treatment after chemotherapy to prevent recurrence
• Clinical trial eligibility: Access to newer therapies

Step 3: Ask These Specific Questions

1. "Based on my genomic results, what are my treatment options?"

   • PARP inhibitors (if BRCA+ or HRD+)
   • Bevacizumab (anti-angiogenic therapy)
   • Immunotherapy trials
   • Standard chemotherapy

2. "Am I eligible for any clinical trials based on my molecular profile?"

   • New drug combinations
   • Precision medicine studies
   • Biomarker-driven trials

3. "How often should my tumor be re-tested?"

   • NCCN Guidelines recommend testing again at recurrence, as mutations can change
   • New mutations may emerge that open new treatment options

4. "What if my results show no mutations?"

   • This doesn't mean treatment won't work—it just means targeted therapies may not apply
   • Standard platinum-based chemotherapy remains effective
   • Bevacizumab may still be recommended

5. "Can I get a copy of my full genomic report?"

   • You have the right to your complete results
   • Helpful for second opinions or future consultations

---

Important Context: How Doctors Use This Information

In the upfront (initial) setting: Genomic profiling helps identify patients who will benefit from PARP inhibitors as maintenance therapy after chemotherapy—potentially extending time without cancer progression.

At recurrence: If your cancer returns, re-testing is important because new mutations may have developed that could respond to different targeted therapies.

According to NCCN Guidelines, testing should be performed in a CLIA-approved laboratory (Clinical Laboratory Improvement Amendments), which ensures quality and accuracy.

---

Key Takeaway

Your genomic profiling results are a personalized "instruction manual" for treating YOUR cancer. The most important findings are usually:

1. BRCA status (opens door to PARP inhibitors)
2. HRD status (predicts chemotherapy and PARP inhibitor response)
3. Other mutations (may identify clinical trial opportunities)

Don't hesitate to ask your oncologist to explain any results you don't understand. These results should directly inform your treatment plan and help you make informed decisions about your care.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.